Dealmaking from Elsevier Business Intelligence

Deals Shaping The Medical Industry, May 2012

Wed, 23 May 2012 00:00:00 -0400

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

Deals Shaping The Medical Industry, April 2012

Mon, 23 Apr 2012 00:00:00 -0400

Deals Shaping The Medical Industry (03/2012)

Mon, 26 Mar 2012 00:00:00 -0400

Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011

Mon, 26 Mar 2012 00:00:00 -0400

Medical device companies raised $800 million in the fourth quarter of 2011, and venture capital represented half of that amount. Just over $4 billion was spent to acquire medical device companies, down 50% from Q3’s $8 billion.

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

Fri, 09 Mar 2012 00:00:00 -0500

Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.

Deals Of The Week: Novartis/Enanta, Ligand/Retrophin, Auxilium/Actelion, Amgen/Dako

Mon, 27 Feb 2012 00:00:00 -0500

A prosaic week in biopharma deal-making leads DOTW to ponder a brain-computer interface specialist’s efforts to apply its technology to patients with severe communication limitations.

Market & Industry Briefs

Fri, 24 Feb 2012 00:00:00 -0500

Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.

Deals Shaping the Medical Industry (2/2012)

Fri, 24 Feb 2012 00:00:00 -0500

Biopharma Out-licensing: 2012’s “In” Thing?

Mon, 13 Feb 2012 00:00:00 -0500

Talk to any Big Pharma business development executive about deal-making trends for more than 15 minutes and the word out-licensing is bound to crop up. Major drugmakers are moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing -- but with qualifications.

Deals Of The Week: Amgen/Micromet, Celgene/Avila, Watson/Ascent

Mon, 30 Jan 2012 00:00:00 -0500

Along with three biotech acquisitions, the week in deal-making also saw the licensing of a new hepatitis C candidate with a different mechanism of action, further consolidation in the animal health field, and the end of Ipsen and Santhera’s collaboration on Alzheimer’s drug fipamezole.

Biopharma Deal-Making In 2011: A Year Of Transition

Mon, 30 Jan 2012 00:00:00 -0500

Approvals jumped, venture retrenched and dealmakers expanded on 2010’s creativity. Pharma’s thirst for payer-friendly innovation and emerging markets infrastructure pushed M&A valuations skyward, and threw VCs and drugmakers closer together.

Deals Shaping The Medical Industry (01/2012)

Tue, 24 Jan 2012 00:00:00 -0500

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents.

Biopharma Out-licensing: 2012’s “In” Thing?

Tue, 24 Jan 2012 00:00:00 -0500

Talk to any big pharma business development executive about dealmaking trends for more than 15 minutes and the word out-licensing is bound to crop up. But are major drugmakers moving beyond the rhetoric and actually giving up rights to individual assets that heretofore would have been deemed too valuable to merit out-licensing?

Deals Shaping The Medical Industry (12/2011)

Tue, 27 Dec 2011 00:00:00 -0500

Deals In Depth: October 2011

Tue, 27 Dec 2011 00:00:00 -0500

October’s dealmaking highlights: Biogen received exclusive global rights to Portola’s autoimmune and anti-inflammatory Syk inhibitors in an alliance worth $554 million. Investment firms took public CRO Pharmaceutical Product Development private for $33.25 per share, or a total of $3.9 billion, including debt.

Deals Shaping The Medical Industry (11/2011)

Wed, 30 Nov 2011 00:00:00 -0500

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)

Wed, 02 Nov 2011 00:00:00 -0400

Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 1 of 2)

Tue, 01 Nov 2011 00:00:00 -0400

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

Tue, 18 Oct 2011 00:00:00 -0400

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

Deals Shaping the Medical Industry (10/2011)

Sat, 01 Oct 2011 00:00:00 -0400

Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development

Sat, 01 Oct 2011 00:00:00 -0400

The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging.

IND Over POC: The New Sweet Spot For Biopharma Dealmaking

Sat, 01 Oct 2011 00:00:00 -0400

Though clinical proof-of-concept has long been the goal of fledgling biotechs hoping to land a deep-pocketed partner or acquirer, data suggest reaching this inflection point may no longer provide an optimal risk-reward balance. Biotechs would be wise to partner earlier.

Deals Shaping the Medical Industry (09/2011)

Thu, 01 Sep 2011 00:00:00 -0400

Adimab Inks Novo, Biogen Deals, On Track to Double Partnered Programs for Second Straight Year

Tue, 30 Aug 2011 00:00:00 -0400

Adimab LLC, a purveyor of yeast-based antibody discovery technology, has quickly generated positive cash flow through deal making and is on pace to double its number of partnered candidate programs for the second straight year

Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India

Wed, 20 Jul 2011 00:00:00 -0400

WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts

Deals Shaping the Medical Industry (07/2011)

Fri, 01 Jul 2011 00:00:00 -0400

Forma To Play To Its Strengths WIth Genentech Deal

Fri, 01 Jul 2011 00:00:00 -0400

Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.

Deals Shaping the Medical Industry (06/2011)

Wed, 01 Jun 2011 00:00:00 -0400

Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 2 of 2)

Wed, 04 May 2011 00:00:00 -0400

Arjun Oberoi, Sanofi-Aventis' vice president for business development Asia Pacific, mirrors his company's leadership ambitions in the Asian markets. Open to calculated risks and high on energy, Oberoi has played a leading role in clinching a few important deals for Sanofi such as last year's acquisition of China OTC play BMP Sunstone and its joint venture with Minsheng Pharmaceutical Group ('Sanofi Expands Consumer Health Reach With New Joint Venture In China,' PharmAsia News, Feb. 1, 2010).

Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 1 of 2)

Tue, 03 May 2011 00:00:00 -0400

What New Cancer Pathway Programs Mean For The Drug Industry

Sun, 01 May 2011 00:00:00 -0400

New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.

Oncology Dealmaking In The Wake Of Changing Regulatory And Reimbursement Decisions

Sun, 01 May 2011 00:00:00 -0400

As big drugmakers move wholeheartedly into oncology, changing regulatory and reimbursement standards have dramatic implications for dealmaking - especially for smaller venture-backed start-ups who hope to sign lucrative alliances or M&A deals with deeper-pocketed partners.

Deals Shaping the Medical Industry (05/2011)

Sun, 01 May 2011 00:00:00 -0400

Bayer Head Of Global Drug Discovery Andreas Busch: An Interview With "The Pink Sheet" DAILY (Part 1 Of 2)

Tue, 26 Apr 2011 00:00:00 -0400

Busch, who oversees pharma R&D through proof-of-concept, talks about the company's research strategy and plans to boost deal-making, with an emphasis on personalized medicine.

Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

Fri, 22 Apr 2011 00:00:00 -0400

Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth

Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

Fri, 22 Apr 2011 00:00:00 -0400

The Swiss drug company has set a goal of generating 60% of sales in emerging markets by 2015.

Pharma Could Be Going Back To Negotiating Table On Federal Drug Cost Cuts

Mon, 18 Apr 2011 00:00:00 -0400

After its protracted deal-making on the health care reform bill in 2009 and 2010, the biopharmaceutical industry may be headed back to negotiations with the White House on proposals to cut drug spending in Medicare.

Tracking Big Pharma's Appetite For Regional Deals

Fri, 01 Apr 2011 00:00:00 -0400

A review of Big Pharma regional dealmaking in 2006-2010 shows a slower uptick in the number of alliances than the steady year-over-year growth seen from 2001-2006.

Deals Shaping the Medical Industry (04/2011)

Fri, 01 Apr 2011 00:00:00 -0400

What's Fueling The Recent Diagnostics Dealmaking?

Fri, 01 Apr 2011 00:00:00 -0400

A variety of new players have become active dealmakers around personalized medicine diagnostics tests and services. One way to put these deals in context is to view the acquired assets through the lens of how they are to be deployed.

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now

Tue, 01 Mar 2011 00:00:00 -0500

Sanofi-Aventis' much publicized pursuit - first hostile, then friendly - of Genzyme dominated biopharma news flow for more than half a year, with well timed information leaks and dramatic "he said, he said" commentary from the firms' CEOs. Such back and forth ensured continued high profile coverage until the companies officially affianced.

Deals Shaping the Medical Industry (03/2011)

Tue, 01 Mar 2011 00:00:00 -0500

Private Grünenthal Aims For Leadership In Pain

Mon, 21 Feb 2011 00:00:00 -0500

Family-owned Grünenthal GMBH has opened up to the outside world, significantly stepping up deal-making as it aims for "global innovation leadership" in pain management.

Deals Shaping the Medical Industry (02/2011)

Tue, 01 Feb 2011 00:00:00 -0500

2010's Top Biopharma Dealmakers

Sat, 01 Jan 2011 00:00:00 -0500

Generics, emerging markets, orphan diseases and earn-out heavy M&A were the recurring dealmaking themes in 2010. We focus here on the dealmakers, showing which companies dominated the dealmaking landscape in terms of deal volume and value, as well as the therapeutic categories that grabbed the most attention.

Deals Shaping the Medical Industry (01/2011)

Sat, 01 Jan 2011 00:00:00 -0500

Personalized Medicine In 2010: Welcome To The Establishment

Sat, 01 Jan 2011 00:00:00 -0500

Evidence of progress for molecular diagnostics and instrumentation, the mainstays of the personalized medicine toolkit, was considerable in 2010. Much of the activity centered on sequencing, although its general utility in clinical diagnostics has not yet been demonstrated and whether measurements of gene expression can form the basis for a plethora of molecular tests also remains an open question.

More Deal Of The Year Nominees

Mon, 20 Dec 2010 00:00:00 -0500

It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.

Deals Of The Year Nominees

Mon, 13 Dec 2010 00:00:00 -0500

Ablexis' Pharmaceutical Consortium

Wed, 01 Dec 2010 00:00:00 -0500

Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.